These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38262629)

  • 1. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil.
    Ridolfi F; Amorim G; Peetluk LS; Haas DW; Staats C; Araújo-Pereira M; Cordeiro-Santos M; Kritski AL; Figueiredo MC; Andrade BB; Rolla VC; Sterling TR;
    J Infect Dis; 2024 Mar; 229(3):813-823. PubMed ID: 38262629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil.
    Possuelo LG; Castelan JA; de Brito TC; Ribeiro AW; Cafrune PI; Picon PD; Santos AR; Teixeira RL; Gregianini TS; Hutz MH; Rossetti ML; Zaha A
    Eur J Clin Pharmacol; 2008 Jul; 64(7):673-81. PubMed ID: 18421452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
    Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
    Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes.
    Peetluk LS; Rebeiro PF; Ridolfi FM; Andrade BB; Cordeiro-Santos M; Kritski A; Durovni B; Calvacante S; Figueiredo MC; Haas DW; Liu D; Rolla VC; Sterling TR;
    Clin Infect Dis; 2022 Mar; 74(6):973-982. PubMed ID: 34214166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.
    Yee J; Kim SM; Han JM; Lee N; Yoon HY; Gwak HS
    Sci Rep; 2020 Feb; 10(1):3658. PubMed ID: 32107440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
    Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa.
    Mouton JP; Njuguna C; Kramer N; Stewart A; Mehta U; Blockman M; Fortuin-De Smidt M; De Waal R; Parrish AG; Wilson DPK; Igumbor EU; Aynalem G; Dheda M; Maartens G; Cohen K
    Medicine (Baltimore); 2016 May; 95(19):e3437. PubMed ID: 27175644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study.
    Arriaga MB; Torres NMC; Araujo NCN; Caldas SCC; Andrade BB; Netto EM
    PLoS One; 2019; 14(12):e0227101. PubMed ID: 31877199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.
    Araujo-Mariz C; Militão de Albuquerque MFP; Lopes EP; Ximenes RAA; Lacerda HR; Miranda-Filho DB; Lustosa-Martins BB; Pastor AFP; Acioli-Santos B
    Ann Hepatol; 2020; 19(2):153-160. PubMed ID: 31734174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Longer the Therapy, the Worse the Severity of the Adverse Drug Reactions that Occur in Drug-Resistant Pulmonary Tuberculosis Patients.
    Susilo R; Azzahra DN; Indawati I; Bachtiar A; Setyaningsih I; Rohadi D; Tomi ; Kustini
    Indian J Tuberc; 2024; 71 Suppl 1():S97-S100. PubMed ID: 39067964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
    Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-Chapoñan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
    Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adverse drug reactions on the outcomes of tuberculosis treatment.
    Sant Anna FM; Araújo-Pereira M; Schmaltz CAS; Arriaga MB; Andrade BB; Rolla VC
    PLoS One; 2023; 18(2):e0269765. PubMed ID: 36749743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.
    Hou ZD; Xiao ZY; Gong Y; Zhang YP; Zeng QY
    BMC Pharmacol Toxicol; 2014 Nov; 15():64. PubMed ID: 25413361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients.
    Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
    Sci Rep; 2023 Jul; 13(1):11438. PubMed ID: 37454203
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Richardson M; Kirkham J; Dwan K; Sloan DJ; Davies G; Jorgensen AL
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):293-305. PubMed ID: 30871660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study.
    Choi H; Park HA; Hyun IG; Kim JH; Hwang YI; Jang SH; Sim YS; Shin TR; Ko Y; Ban GY; Hong JY; Lee CY; Lee MG; Choi JH
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1153-1163. PubMed ID: 35909258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Burden of Adverse Drug Reactions to Isoniazid Preventive Therapy in People Living With HIV at 3 Tertiary Hospitals in Uganda: Associated Factors.
    Nanyonga SM; Kitutu FE; Kalyango J; Frank M; Kiguba R
    J Acquir Immune Defic Syndr; 2022 Feb; 89(2):215-221. PubMed ID: 34693930
    [TBL] [Abstract][Full Text] [Related]  

  • 19.  NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population.
    Lv X; Tang S; Xia Y; Zhang Y; Wu S; Yang Z; Li X; Tu D; Chen Y; Deng P; Ma Y; Chen D; Chen R; Zhan S
    Ann Hepatol; 2012; 11(5):700-7. PubMed ID: 22947533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensory polyneuropathy in human immunodeficiency virus-infected patients receiving tuberculosis treatment.
    Centner CM; Carrara H; Harrison TB; Benatar M; Heckmann JM
    Int J Tuberc Lung Dis; 2014 Jan; 18(1):27-33. PubMed ID: 24365548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.